iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia
March 13, 2025
SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia, today announced that it has closed its fully subscribed Series B-2 financing of $3 million.
This investment will support iVeena’s pursuit of advancing their innovative pediatric myopia program. All IND-enabling studies are well underway supporting a targeted IND submission in H1-2025.
“We are pleased to welcome Dr. Jerry Hu to our Board as an independent director,” said President and Founder, Bala Ambati, M.D., Ph.D., MBA. “Dr. Hu is a world-renowned ophthalmologist who stands at the forefront of cutting-edge ophthalmic innovations bringing significant value to our long-term strategy.”
Recent News
- Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research
- The 2025 Wilson Sonsini E&I Summit Attracts Over 400 Participants
- First Patient Enrolled in Merit Medical’s PREEMIE Study
- iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia
- Altitude Lab Demo Day
- Steve Pacelli Appointed CEO of Epitel, Inc.
